Natures Sunshine Products Stock (NASDAQ: NATR)

Natures Sunshine Products (NASDAQ:NATR) Stock, Quote.Headers.trade-ideas

Natures Sunshine Products

Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.

Business,Analyst,Checking,In,Financial,Statement,For,Audit,Internal,Control

Analyst Color

Equities

News

Price Target

Initiation

Markets

Analyst Ratings

Trading Ideas

General

NATR

Analyst Susan Anderson projects Nature&#39;s Sunshine Products to achieve a 15% adjusted EBITDA margin by FY28, driven by digital growth, international expansion, and innovation.

Nature&#39;s Sunshine To Gain From Margin Expansion - Analyst Projects 15% Adjusted EBITDA Margin By FY28

wall-street-ai17

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Penny Stocks

Small Cap

Intraday Update

Movers

ADTH

AIRE

ANNX

ATER

BGNE

BIRD

BTOG

CLOV

CMTL

DLTR

ECDA

EDUC

GXAI

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HRTX

Kintara Therapeutics, Inc. - Common Stock

KTRA

LICY

LUNA

MINM

MNMD

NAAS

NCNA

NMRA

PIII

PRTG

RXRX

SIGA

SKIN

SMMT

SURG

SWIN

VERI

VJET

Shares of  Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products Inc

Canaccord Genuity analyst Susan Anderson initiated coverage on Nature&#8217;s Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) with a Buy rating <a target="_blank" href="https://www.benzinga.com/quote/NATR/analyst-ratings" rel="noreferrer noopener">and a price forecast of&nbsp;$18.</a>
The analyst highlights that the company&#8217;s products are distributed in over 40 countries, with Asia leading at 45% of sales, North America at 31%, Europe at 18%, and LATAM and other regions at 8% as of FY23.
According to the analyst, Nature&#8217;s Sunshine is poised for margin expansion as it increases sales through three key strategies: investing in the higher-margin, rapidly growing digital sector, expanding its international presence in critical markets, and driving innovation in a sector with rising consumer interest.
Anderson writes these initiatives should allow the company to reach the 15% adjusted EBITDA margin goals by FY28, up from ~9% in FY23.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40859088/kkr-aims-to-replicate-european-private-equity-success-report" rel="noreferrer noopener">KKR Aims To Replicate European Private Equity Success: Report</a>
The analyst points out that, given the global shift towards greater health awareness post-pandemic, the company is well-positioned to capture a substantial share of the expanding market.
According to the analyst, the company&#8217;s gross margins could improve through greater product innovation, a shift towards higher-margin digital products, and relief from cost inflation and currency headwinds.
The analyst forecasts that if sales grow at a low-single-digit CAGR, management could enhance operating expenses by approximately 300 basis points.
Anderson projects FY24 adjusted EPS of $0.54, with net sales of $439.5 million.
Price Action: NATR shares are trading higher by 6.26% to $14.08 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40858884/wall-street-aims-for-fifth-straight-gain-small-caps-soar-as-2-ye" target="_blank" rel="noreferrer noopener">Wall Street Aims For Fifth Straight Gain, Small Caps Soar As 2-Year Yields Hit 2-Year Lows, Adobe Sinks: What&#8217;s Driving Markets Friday?</a></li>
</ul>

Nature's Sunshine To Gain From Margin Expansion - Analyst Projects 15% Adjusted EBITDA Margin By FY28

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>BMO Capital analyst Ameet Thakkar initiated coverage on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with an Outperform rating and announced a price target of $245. GE Vernova shares gained 2.9% to close at $215.27 on Thursday. See how other analysts view this stock.</li>
<li>Raymond James analyst Srini Pajjuri initiated coverage on Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with an Outperform rating and announced a price target of $160. ARM shares fell 0.8% to close at $139.18 on Thursday. See how other analysts view this stock.</li>
<li>Canaccord Genuity analyst Susan Anderson initiated coverage on Nature&#8217;s Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) with a Buy rating and announced a price target of $18. Natures Sunshine Products shares gained 1.2% to close at $13.25 on Thursday. See how other analysts view this stock.</li>
<li>CLSA initiated coverage on NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) with an Outperform rating and announced a price target of $11. NuScale Power shares fell 1.3% to close at $8.63 on Thursday. See how other analysts view this stock.</li>
<li>Jefferies analyst Paul Zimbardo initiated coverage on Public Service Enterprise Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) with a Hold rating and announced a price target of $85. Public Service Enterprise shares rose 1.4% to close at $83.31 on Thursday. See how other analysts view this stock.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40850889/4m-bet-on-this-energy-stock-check-out-these-3-stocks-executives-are-buying">$4M Bet On This Energy Stock? Check Out These 3 Stocks Executives Are Buying</a></li>
</ul>

Canaccord Genuity analyst Susan Anderson initiates coverage on Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) with a Buy rating and announces Price Target of $18.

Canaccord Genuity Initiates Coverage On Natures Sunshine Products with Buy Rating, Announces Price Target of $18

The facility was evacuated and local emergency services were called to the scene to help manage the incident. All personnel&nbsp;are&nbsp;safe and&nbsp;accounted for, and two&nbsp;individuals&nbsp;were seen by EMTs and released to leave the facility.
The company is working to determine the cause of the&nbsp;malfunction, which resulted in a small fire,&nbsp;and to assess the extent of the damage to the facility.&nbsp;
A portion of the facility will temporarily be closed for repairs while normal operations continue in unaffected areas.

Nature's Sunshine Says An Equipment Malfunction Occurred At Its Spanish Fork, Utah Manufacturing Facility Early Yesterday Morning

DA Davidson analyst Linda Bolton Weiser maintains Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) with a Buy and lowers the price target from $23 to $21.

DA Davidson Maintains Buy on Natures Sunshine Products, Lowers Price Target to $21

WIIM

Nature's Sunshine Products shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered FY24 net sales guidance.

Guidance

Nature's Sunshine Products Sees FY24 Net Sales $436M-$445M (Prior $455M-$480M)

Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.25 by 72 percent. The company reported quarterly sales of $110.551 million which missed the analyst consensus estimate of $112.280 million by 1.54 percent. This is a 5.15 percent decrease over sales of $116.548 million the same period last year.

Earnings

Earnings Misses

Natures Sunshine Products Q2 2024 Adj. EPS $0.07 Misses $0.25 Estimate, Sales $110.551M Miss $112.280M Estimate

Nature's Sunshine shares are trading lower after the company reported worse-than-expected Q1 financial results.

Natures Sunshine Products Sees FY24 Net Sales $455M-$480M Vs $467.900M Est.

Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.17 by 29.41 percent. This is a 47.83 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $110.993 million which missed the analyst consensus estimate of $111.200 million by 0.19 percent. This is a 2.17 percent increase over sales of $108.634 million the same period last year.

Natures Sunshine Products Q1 2024 Adj EPS $0.12 Misses $0.17 Estimate, Sales $110.993M Miss $111.200M Estimate

Shares of Clover Health Investments, Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clov#NASDAQ">CLOV</a>) rose sharply during Wednesday&rsquo;s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.
Clover Health Investments reported quarterly sales of $510.3 million which beat the analyst consensus estimate of $480.25 million by 6.26% and represents a 43.22% decrease over sales of $898.79 million the same period last year.
Clover Health Investments shares climbed 11.2% to $0.8537 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Gaxos.ai Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gxai#NASDAQ">GXAI</a>) shares jumped 128.9% to $12.18 after the company announced it acquired the rights to use certain AI-enabled technology from Ultiself.</li>
<li>Veritone, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veri#NASDAQ">VERI</a>) gained 52.4% to $2.6076 following strong sales results.</li>
<li>NuCana plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncna#NASDAQ">NCNA</a>) gained 50.2% to $0.5869 after the company was granted a US Patent for &quot;Phosphoramidate Derivatives For Use In The Treatment Of Cancer; Especially In The Treatment Where The Patient Shows Resistance.&quot;</li>
<li>The Beauty Health Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skin#NASDAQ">SKIN</a>) rose 31.9% to $4.7350 after the company reported better-than-expected fourth-quarter revenue results.</li>
<li>Arq, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arq#NASDAQ">ARQ</a>) gained 28.3% to $4.4522 after the company reported upbeat fourth-quarter results.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) jumped 26.6% to $6.19.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares gained 26.2% to $0.1055.</li>
<li>Nature&#39;s Sunshine Products, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/natr#NASDAQ">NATR</a>) jumped 24.7% to $21.47 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 net sales guidance.</li>
<li>Heron Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrtx#NASDAQ">HRTX</a>) gained 24.7% to $2.9428 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $4 to $5.</li>
<li>Li-Cycle Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/licy#NASDAQ">LICY</a>) shares gained 23.2% to $0.7233. Li-Cycle shares jumped 46% on Tuesday after the company entered an agreement to issue a senior secured convertible note in an aggregate principal amount of $75 million to an affiliate of Glencore.</li>
<li>Cue Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cue#NASDAQ">CUE</a>) gained 19.2% to $2.11 after Jefferies initiated coverage on the stock with a Buy rating and $6 price target.</li>
<li>AdTheorent Holding Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adth#NASDAQ">ADTH</a>) surged 19% to $3.4150 following strong sales.</li>
<li>SIGA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/siga#NASDAQ">SIGA</a>) gained 18.8% to $6.32 after the company reported a year-over-year increase in quarterly financial results.</li>
<li>Educational Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/educ#NASDAQ">EDUC</a>) surged 18.1% to $2.0432.</li>
<li>Portage Biotech Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtg#NASDAQ">PRTG</a>) gained 17.7% to $0.6589.</li>
<li>Williams-Sonoma, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wsm#NYSE">WSM</a>) climbed 17.7% to $283.70 after the company reported better-than-expected fourth-quarter earnings, announced a new $ 1 billion stock repurchase authorization and increased its quarterly dividend.</li>
<li>HUTCHMED (China) Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcm#NASDAQ">HCM</a>) shares climbed 15.8% to $18.91 after gaining 9% on Tuesday.</li>
<li>Annexon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/annx#NASDAQ">ANNX</a>) rose 15% to $5.28. Needham analyst Joseph Stringer reiterated Annexon with a Buy and maintained a $16 price target.</li>
<li>Mind Medicine (MindMed) Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnmd#NASDAQ">MNMD</a>) gained 13.2% to $8.90.</li>
<li>Full Truck Alliance Co. Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ymm#NYSE">YMM</a>) climbed 11.2% to $7.74. Full Truck Alliance announced extension of share repurchase program up to $300 million.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) gained 10% to $4.7450.</li>
<li>Qilian International Holding Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qli#NASDAQ">QLI</a>) climbed 10% to $0.6052.</li>
<li>PBF Energy Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbf#NYSE">PBF</a>) gained 9.4% to $55.18.</li>
<li>BeiGene, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgne#NASDAQ">BGNE</a>) shares climbed 9% to $178.44.</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) gained 8.3% to $5.43 after the company announced that it entered into a definitive merger agreement with e2Companies.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) rose 7% to $ 11.27.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>voxeljet AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vjet#NASDAQ">VJET</a>) shares fell 40.8% to $0.5922 after the company announced it will voluntarily delist its ADSs from Nasdaq and deregister its ADSs. The company also announced the restatement and extension of its loan financing with Anzu.</li>
<li>Luna Innovations Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/luna#NASDAQ">LUNA</a>) fell 39% to $3.82 after the company announced that it will delay the release of its fourth-quarter and FY23 financial results. and said financial statements for the quarters ended Jun. 30 and Sept. 30 should no longer be relied upon.</li>
<li>SurgePays, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/surg#NASDAQ">SURG</a>) fell 30.5% to $4.86 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>P3 Health Partners Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/piii#NASDAQ">PIII</a>) fell 29.4% to $0.72.</li>
<li>SOS Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sos#NYSE">SOS</a>) dipped 28% to $1.5399 G</li>
<li>Allbirds, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bird#NASDAQ">BIRD</a>) declined 25.3% to $0.6952 after the company reported worse-than-expected fourth-quarter GAAP EPS results.</li>
<li>Fangdd Network Group Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duo#NASDAQ">DUO</a>) fell 23.3% to $0.5710.</li>
<li>WideOpenWest, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wow#NYSE">WOW</a>) fell 21.1% to $2.7290 after the company reported worse-than-expected fourth-quarter financial results and issued guidance.</li>
<li>NaaS Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/naas#NASDAQ">NAAS</a>) fell 20.1% to $1.19 after the company announced a $6 million registered direct offering.</li>
<li>Comtech Telecommunications Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmtl#NASDAQ">CMTL</a>) fell 19% to $4.6599. Comtech named John Ratigan as Interim Chief Executive Officer.</li>
<li>Aterian, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ater#NASDAQ">ATER</a>) tumbled 19% to $0.3783 following quarterly results.</li>
<li>Psyence Biomedical Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbm#NASDAQ">PBM</a>) fell 17.8% to $1.01.</li>
<li>reAlpha Tech Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aire#NASDAQ">AIRE</a>) fell 16.3% to $1.07 after the company reported EPS for the eight months ended Dec. 31, 2023.</li>
<li>loanDepot, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ldi#NYSE">LDI</a>) fell 15.9% to $2.1350 following weak quarterly results.</li>
<li>Bit Origin Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btog#NASDAQ">BTOG</a>) fell 15.7% to $4.45 after gaining 11% on Tuesday.</li>
<li>Dollar Tree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dltr#NASDAQ">DLTR</a>) declined 14.5% to $128.00 after the company reported worse-than-expected fourth-quarter financial results and issued first-quarter EPS guidance below estimates.</li>
<li>Rackspace Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxt#NASDAQ">RXT</a>) dipped 13.3% to $1.9150 after the company issued first-quarter guidance below estimates. The company also announced refinancing transactions.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zim#NYSE">ZIM</a>) fell 12.4% to $10.22 following weak quarterly sales.</li>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) declined 12.2% to $15.24.</li>
<li>ECD Automotive Design, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ecda#NASDAQ">ECDA</a>) dipped 10.8% to $1.07 after jumping over 13% on Tuesday.</li>
<li>Solowin Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swin#NASDAQ">SWIN</a>) fell 8.6% to $26.61.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/03/37657561/nvidia-to-rally-around-20-here-are-10-top-analyst-forecasts-for-wednesday"> NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday </a>

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Nature's Sunshine Products are trading higher after the company reported better-than-expected Q4 adjusted EPS.

DA Davidson analyst Linda Bolton Weiser maintains Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) with a Buy and raises the price target from $21.5 to $24.

DA Davidson Maintains Buy on Natures Sunshine Products, Raises Price Target to $24

Nature's Sunshine Products are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 net sales guidance.

The Company expects full year 2024&nbsp;adjusted EBITDA to range between&nbsp;$42&nbsp;-&nbsp;$48 million.

Nature's Sunshine Expects Full Year 2024 Net Sales To Range $455M-$480M, Est $464.277M

Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.15 by 200 percent. The company reported quarterly sales of $108.936 million which missed the analyst consensus estimate of $111.133 million by 1.98 percent. This is a 6.02 percent increase over sales of $102.749 million the same period last year.

Earnings Beats

Natures Sunshine Products Q4 2023 Adj EPS $0.45 Beats $0.15 Estimate, Sales $108.936M Miss $111.133M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is likely to report earnings for its fourth quarter.
&bull; MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $530.30 million.
&bull; BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) is likely to report quarterly loss at $0.91 per share on revenue of $710 thousand.
&bull; Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $45.27 million.
&bull; Tupperware Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) is estimated to report earnings for its second quarter.
&bull; Kanzhun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $214.08 million.
&bull; Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is projected to report quarterly loss at $0.22 per share on revenue of $222.43 million.
&bull; FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $34.53 million.
&bull; Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) is projected to report quarterly earnings at $1.43 per share on revenue of $23.64 billion.
&bull; On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $510.19 million.
&bull; Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is projected to report quarterly earnings at $0.51 per share on revenue of $16.09 million.
&bull; Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $-250 thousand.
&bull; Kohl&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is estimated to report quarterly earnings at $1.28 per share on revenue of $5.70 billion.
&bull; PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWFL#NASDAQ">PWFL</a>) is likely to report quarterly loss at $0.10 per share on revenue of $34.34 million.
&bull; Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $197.93 million.
&bull; IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $476.18 million.
&bull; Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $123.96 million.
&bull; Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.24 million.
&bull; Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly loss at $0.10 per share on revenue of $201.84 million.
&bull; Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) is estimated to report earnings for its fourth quarter.
&bull; Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $245.27 million.
&bull; ATRenew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) is projected to report earnings for its fourth quarter.
&bull; Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $70.75 million.
&bull; Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) is projected to report quarterly earnings at $0.41 per share on revenue of $1.11 billion.
&bull; Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is projected to report quarterly loss at $0.13 per share on revenue of $48.40 million.
<h3>Companies Reporting After The Bell</h3>
&bull; ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $6.53 million.
&bull; Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $172.68 million.
&bull; MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $13.09 million.
&bull; Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $111.13 million.
&bull; Performant Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $31.59 million.
&bull; Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $0.98 per share on revenue of $592.58 million.
&bull; Arq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQ#NASDAQ">ARQ</a>) is likely to report quarterly loss at $0.08 per share on revenue of $27.00 million.
&bull; Rackspace Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) is projected to report quarterly loss at $0.04 per share on revenue of $714.72 million.
&bull; Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $45.74 million.
&bull; Intl General Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) is likely to report earnings for its fourth quarter.
&bull; Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) is projected to report quarterly loss at $0.15 per share on revenue of $13.48 million.
&bull; Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $0.27 per share on revenue of $1.60 million.
&bull; Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $33.52 million.
&bull; Maiden Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHLD#NASDAQ">MHLD</a>) is likely to report earnings for its fourth quarter.
&bull; SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) is likely to report earnings for its fourth quarter.
&bull; Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) is projected to report quarterly loss at $2.00 per share on revenue of $2.10 million.
&bull; Doma Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOMA#NYSE">DOMA</a>) is likely to report quarterly loss at $1.30 per share on revenue of $69.42 million.
&bull; Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.07 per share on revenue of $87.63 million.
&bull; Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $8.74 million.
&bull; Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is projected to report quarterly loss at $0.13 per share on revenue of $29.34 million.
&bull; Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $4.43 million.
&bull; Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) is expected to report quarterly loss at $0.16 per share on revenue of $30.97 million.
&bull; AdTheorent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTH#NASDAQ">ADTH</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $56.20 million.
&bull; Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) is likely to report quarterly loss at $0.03 per share on revenue of $30.00 million.
&bull; Oportun Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $262.30 million.
&bull; icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is likely to report quarterly loss at $0.05 per share on revenue of $4.30 million.
&bull; Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.18 per share on revenue of $145.56 million.
&bull; Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $73.07 million.
&bull; Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is likely to report quarterly loss at $1.38 per share on revenue of $1.06 million.
&bull; Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.03 per share on revenue of $13.60 million.
&bull; loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $236.76 million.
&bull; CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is estimated to report quarterly loss at $0.29 per share on revenue of $58.40 million.
&bull; Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) is likely to report quarterly loss at $0.10 per share on revenue of $42.84 million.
&bull; Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $480.25 million.
&bull; Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $226.02 million.
&bull; Eastern Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EML#NASDAQ">EML</a>) is likely to report earnings for its fourth quarter.
&bull; BRT Apartments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRT#NYSE">BRT</a>) is estimated to report earnings for its fourth quarter.
&bull; Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is expected to report quarterly loss at $0.06 per share on revenue of $87.21 million.
&bull; Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is likely to report quarterly loss at $0.11 per share on revenue of $151.50 million.
&bull; Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) is projected to report quarterly loss at $0.23 per share on revenue of $69.06 million.
&bull; Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $47.25 million.
&bull; PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $9.37 million.
&bull; Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is likely to report quarterly loss at $0.15 per share on revenue of $33.79 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ALGS

AWRE

BLDE

BTAI

BTMD

CLPT

CLSD

CRMD

CSBR

CYRX

DOMA

ENFN

GHLD

HGTY

ICAD

IGIC

INVE

LCUT

MANU

MHLD

MNSO

MXCT

NOTE

NRGV

ONON

OPRT

PFMT

PHUN

PRPL

PRTH

PWFL

QFIN

QRHC

REFI

RERE

SNCR

SWIM

TACT

TNON

WEST

WKHS

Earnings Scheduled For March 12, 2024

Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-12. Here's what investors need to know before the announcement.
Analysts estimate that Natures Sunshine Products will report an earnings per share (EPS) of $0.15. 
Natures Sunshine Products bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at Natures Sunshine Products's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.15</td>
<td>0.12</td>
<td>0.23</td>
<td>0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Natures Sunshine Products were trading at $17.85 as of March 08. Over the last 52-week period, shares are up 75.76%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/NATR/earnings">To track all earnings releases for Natures Sunshine Products visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Natures Sunshine Products's Earnings

Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It&rsquo;s no wonder vitamin supplements are a multi-billion dollar business, projected to hit a market size of <a href="https://www.alliedmarketresearch.com/press-release/vitamin-supplements-market.html">$98 billion</a> in less than a decade. While vitamin supplements have been around since the early 1900s, it wasn&rsquo;t until the late 1950s that they took off with the masses as consumers adopted healthier lifestyles and awareness grew about their benefits.
Today, there are vitamins for everything from improving gut health to slowing aging. A survey conducted in 2019 found that more than <a href="https://osteopathic.org/2019/01/16/poll-finds-86-of-americans-take-vitamins-or-supplements-yet-only-21-have-a-confirmed-nutritional-deficiency/">four in five Americans take vitamins or supplements</a>.&nbsp;&nbsp;
The regenerative wellness sector may be following a similar trajectory, where stem cells are playing a leading role in wellness and anti-aging thanks to their self-renewal ability. Stem cells have the potential to <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276428/#:~:text=Adipose%2Dderived%20mesenchymal%20stem%20cells&amp;text=In%20terms%20of%20anti%2Daging,cell%20regeneration%20through%20paracrine%20action.">regenerate cells, tissues and organs</a> in the body, improving people&rsquo;s quality of life and slowing the aging process. Studies have shown the more stem cells you have circulating in your blood, the greater the ability of your body to renew itself &ndash; naturally.
<h3>Stem Cells Turn Back The Clock&nbsp;</h3>
Stem cells&rsquo; rejuvenating abilities are already making it a big business, one that seems poised for more growth in the years to come, following in the footsteps of the vitamin industry. The stem cell market is projected to hit <a href="https://www.visionresearchreports.com/stem-cells-market/39760">$32 billion by 2030</a>, growing at a CAGR of 11.57%. That compares to the global vitamin supplements market which <a href="https://www.alliedmarketresearch.com/vitamin-supplements-market-A16898#:~:text=Vitamin%20Supplements%20Market%20Research%2C%202031,7.6%25%20from%202022%20to%202031.">reached $47.9 billion in 2021</a> and is projected to hit $98.6 billion by 2031, growing at a CAGR of 7.6%. In its early days, the vitamin supplements market had double-digit growth, similar to what the stem cell market is seeing.&nbsp;
One company planning to ride this burgeoning trend is Stemtech Corporation (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/stek#OTCQB">STEK</a>), the <a href="https://www.stemtech.com/us">Naples, Florida company</a> that develops science-based products to support wellness using the body&rsquo;s own stem cells. Stemtech says its stem cell enhancers improve the body&rsquo;s natural defense, renewal, rejuvenation and anti-aging processes. Its products also boast powerful anti-aging components, which is proving popular with its many loyal customers. The company reports that sales are steadily increasing quarter over quarter and more of the same is expected in 2024. That growth is being driven by demand for its products and its network of distributors known as Independent Business Partners (IBPs) eager to sell Stemtech&rsquo;s stem cell-based supplements. &quot;Stemtech is witnessing the increase in the number of our IBP Independent Business Partners network. This positive momentum is a testament to the appeal of Stemtech&#39;s exceptional anti-aging products and the promising income-earning opportunity we offer,&quot; Stemtech President and COO John W. Meyer said <a href="https://www.stemtech.com/us/Company/Investors?subnav=NAM">in a recent press release</a>.&nbsp;
Stemtech isn&rsquo;t the only player in the stem cell market, several transformative health companies are going after different areas including Sprouts Farmers Market (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfm#NASDAQ">SFM</a>), Amphastar Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amph#NASDAQ">AMPH</a>), OPKO Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>), Herbalife Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NASDAQ">HLF</a>), Natural Grocers by Vitamin Cottage Inc. (NGVC), Nature&#39;s Sunshine Products Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/natr#NASDAQ">NATR</a>) and Henry Schein Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsic#NASDAQ">HSIC</a>).
<h3>Stemtech&rsquo;s Edge</h3>
Thanks to the science its approach is based on, Stemtech believes it has an edge over other players in the stem cell enhancing market. Stemrelease3&trade;, Stemtech&rsquo;s most advanced stem cell nutrition product, contains stemrelease3, a blend of clinically tested ingredients that Stemtech says help release millions of your body&rsquo;s own stem cells from the bone marrow into the bloodstream. The company says stemrelease3 also helps support telomere health, which is a potent defense to the aging process.&nbsp;
<a href="https://www.stemtech.com/us/Products/RCM">The RCM System, its flagship</a> system, is comprised of three products: Stemrelease3&trade;, StemFlo Advanced&reg; and MigraStem&trade; also containing superfood extracts, antioxidants, polysaccharides, vitamins, minerals and other natural compounds. These are designed to support the healthy activity of our stem cells and boost the immune and circulatory system functions. The nutrients in RCM also help to activate the energy processes in the mitochondria, have antioxidant and detoxification effects and support telomere health, according to Stemtech.&nbsp;
&nbsp;
Stemtech&rsquo;s <a href="https://www.stemtech.com/us/Products/CellectOne">Cellect One&trade; Rapid Renew Stem Cell Peptide Night Cream</a> is another product the company reports is popular. It uses patented ingredient QXP from Red Oak Bark to lower the skin&#39;s barriers so stem cells and peptides containing antioxidants and proteins can penetrate deeper into the skin, assisting in improving skin moisture, elasticity and a more youthful look.
The company also offers OraStem&reg;, an all-natural toothpaste that protects, strengthens, rejuvenates, restores and supports your teeth and gum function from the cellular level. In addition, Stemtech says it also provides anti-oxidative and anti-microbial protection, supports your tooth strength with essential minerals, helps to gently remove stains, brightens your teeth in a natural and non-abrasive way and freshens breath.
Stemtech&rsquo;s line of supplements, skin care products and oral care products aims to answer a need among consumers for anti-aging and wellness products that actually work. What vitamins did for healthy living, stem cells can do for aging. Stemtech is planning to take center stage in this evolution, betting it can play a big role in rejuvenating the body and turning back the clock one stem cell at a time.&nbsp;
Featured photo by <a href="https://unsplash.com/@cdc?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">CDC</a> on <a href="https://unsplash.com/photos/woman-holding-laboratory-appratus-LiNIONbajm4?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Disclaimer: This announcement contains forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as &quot;believes,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;estimates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;targets,&quot; &quot;projects&quot; and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company&#39;s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on December 1, 2023. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
&nbsp;

Biotech

AMPH

HSIC

STEK

What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition

Nature's Sunshine GAAP EPS of $0.12 misses by $0.05, revenue of $111M misses by $0.2M

Nature's Sunshine Products, Inc. (NATR) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Natures Sunshine Products (NASDAQ:<a href="https://investorplace.com/stock-quotes/natr-stock-quote/">NATR</a>) just reported results for the first quarter of 2024.<ul><li>Natures Sunshine Products reported earnings per share of 12 cents. This was below the analyst estimate for EPS of 17 cents.</li><li>The company reported revenue of $110.99 million.</li><li>This was 0.19% worse than the analyst estimate for revenue of $111.20 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/natr-stock-earnings-natures-sunshine-products-for-q1-of-2024/">NATR Stock Earnings: Natures Sunshine Products Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NATR Stock Earnings: Natures Sunshine Products Misses EPS, Misses Revenue for Q1 2024

Andersons and Grand Canyon among Consumer Staples movers

Nature's Sunshine Products Stock: A Cloudy Outlook Into Second Half Of 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Natures Sunshine Products (NASDAQ:<a href="https://investorplace.com/stock-quotes/natr-stock-quote/">NATR</a>) just reported results for the second quarter of 2024.<ul><li>Natures Sunshine Products reported earnings per share of 7 cents. This was below the analyst estimate for EPS of 25 cents.</li><li>The company reported revenue of $110.55 million.</li><li>This was 1.54% worse than the analyst estimate for revenue of $112.28 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/natr-stock-earnings-natures-sunshine-products-for-q2-of-2024/">NATR Stock Earnings: Natures Sunshine Products Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NATR Stock Earnings: Natures Sunshine Products Misses EPS, Misses Revenue for Q2 2024

Nature's Sunshine GAAP EPS of $0.07, revenue of $110.6M

Nature's Sunshine Products, Inc. (NATR) Q2 2024 Earnings Call Transcript

Nature's Sunshine Products, Inc. 2024 Q2 - Results - Earnings Call Presentation

D.A. Davidson analyst Linda Bolton Weiser maintained a Buy rating on Nature's Sunshine Products (NATR – Research Report) today and set a price targ...

Nature's Sunshine Products (NATR) Receives a Buy from D.A. Davidson

ANDE

APEI

BRFS

COOT

DTCK

IPAR

LOPE

SNAX

ZVIA

Press Releases

Nature's Sunshine Recognized with Six Stevie Awards in the 2024 American Business Awards

Gateway Group Announces Preliminary Presenting Companies for Gateway Conference in San Francisco on September 4-5, 2024

Nature's Sunshine Reports Strong First Quarter 2024 Results

Nature's Sunshine Honored with Comparably Awards for Best Leadership Team and Best Career Growth

Gateway Group Announces Preliminary Sponsors and Additional Presenting Companies for September Gateway Conference

Nature's Sunshine Sets Second Quarter 2024 Conference Call for Thursday, August 8, 2024, at 5:00 p.m. ET

Nature's Sunshine Reports Second Quarter 2024 Results

Nature's Sunshine Products to Present at the 2024 Gateway Conference on September 4th, 2024

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Natures Sunshine Products

Natures Sunshine Products (NATR) Forecast

Natures Sunshine Products (NASDAQ:NATR) Stock, Quote.Headers.trade-ideas